Duke University

Fred Hutchinson Cancer Center

City of Hope

Rosetta Inpharmatics, Inc.

Jerald P Radich

Dong-wook Kim

Tannishtha Reya

Hyog Y Kwon

Takahiro Ito

Vivian Oehler

Peter S Linsley

Stephen J Forman

Hongyue Dai

Mao Mao

Janell M Schelter

Ravi Bhatia

Smita Bhatia

Liang Li

Min Li

Lue Ping Zhao

Disclosed are methods of predicting responsiveness of a cancer cell to a tyrosine kinase inhibitor, and methods of predicting the risk of progression of a cancer cell to a more aggressive form. Also provided are methods of reducing proliferation or promoting differentiation of a cancer cell having reduced level of Numb or increased level of Msi. Further disclosed are methods of treating a mammalian subject having cancer and methods of assessing an agent for chemotherapeutic potential.

Diagnostic and treatment for chronic and acute phase myeloid leukemia

In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level.

Gene signatures for prediction of therapy-related myelodysplasia and methods for identification of patients at risk for development of the same

The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec&#x2122;) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec&#x2122; by modulating the expression or activity of these genes and/or their encoded proteins.

Genes associated with progression and response in chronic myeloid leukemia and uses thereof

Growing community of inventors

Seattle, WA, United States of America

Jerald P Radich